Bartoletti, MicheleGiannella, MaddalenaLewis, Russell ECaraceni, PaoloTedeschi, SaraPaul, MicalSchramm, ChristophBruns, TonyMerli, ManuelaCobos-Trigueros, NazaretSeminari, ElenaRetamar, PilarMuñoz, PatriciaTumbarello, MarioBurra, PatriziaTorrani Cerenzia, MariaBarsic, BrunoCalbo, EsterMaraolo, Alberto EnricoPetrosillo, NicolaGalan-Ladero, Maria AngelesD'Offizi, GianpieroZak-Doron, YaelRodriguez-Baño, JesusBaldassarre, MaurizioVerucchi, GabriellaDomenicali, MarcoBernardi, MauroViale, PierluigiESGBIS/BICHROME study group2023-01-252023-01-252019http://hdl.handle.net/10668/13426We analyzed the impact of continuous/extended infusion (C/EI) vs intermittent infusion of piperacillin-tazobactam (TZP) and carbapenems on 30-day mortality of patients with liver cirrhosis and bloodstream infection (BSI). The BICRHOME study was a prospective, multicenter study that enrolled 312 cirrhotic patients with BSI. In this secondary analysis, we selected patients receiving TZP or carbapenems as adequate empirical treatment. The 30-day mortality of patients receiving C/EI or intermittent infusion of TZP or carbapenems was assessed with Kaplan-Meier curves, Cox-regression model, and estimation of the average treatment effect (ATE) using propensity score matching. Overall, 119 patients received TZP or carbapenems as empirical treatment. Patients who received C/EI had a significantly lower mortality rate (16% vs 36%, P = .047). In a Cox-regression model, the administration of C/EI was associated with a significantly lower mortality (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.11-0.936; P = .04) when adjusted for severity of illness and an ATE of 25.6% reduction in 30-day mortality risk (95% CI, 18.9-32.3; P C/EI of beta-lactams in cirrhotic patients with BSI may improve outcomes and facilitate earlier discharge.enbloodstream infectioncontinuous infusionliver cirrhosisβ-lactam antibioticsAgedAnti-Bacterial AgentsBacteremiaFemaleHumansInfusions, IntravenousLiver CirrhosisMaleMiddle AgedPiperacillinProspective StudiesRetrospective StudiesTazobactamTreatment Outcomebeta-Lactamsresearch article30649218open access10.1093/cid/ciz0321537-6591https://iris.uniroma1.it/bitstream/11573/1281310/1/Bartoletti_extended-infusion_2019.pdf